Bridge Pharmaceuticals

Bridge Biotherapeutics is a clinical-stage biotechnology company based in South Korea that focuses on developing novel therapies for inflammation, cancer, and fibrotic diseases. The company operates on a "no-lab" or virtual R&D model, sourcing early-stage assets from academia and other biotechs to advance them through clinical proof-of-concept. Its lead programs include BBT-877, an autotaxin inhibitor for idiopathic pulmonary fibrosis, and several next-generation EGFR inhibitors targeting resistant mutations in non-small cell lung cancer. Bridge Biotherapeutics is publicly traded on the KOSDAQ exchange and maintains a global presence with operations in the United States and China.